How would you treat an older patient with multiple co-morbidities and borderline performance status with resectable esophageal cancer in light of ESOPEC trial?

If triplet chemotherapy is likely too morbid, would you prefer neoadjuvant chemoradiation per CROSS in this setting?

Answer from: Medical Oncologist at Academic Institution

This is a great question. There is lacking data to answer your question, so you are getting my professional opinion and that which I heard discussed at the recent Best of ASCO by Binaytara. The simple answer: yes. We as oncologists need to know the data, know what is "optimal" and individuali...

Please select the option that best describes you:

How would you treat an older patient with multiple co-morbidities and borderline performance status with resectable esophageal cancer in light of ESOPEC trial?

Related Questions